K Kashfi

Summary

Affiliation: City University of New York
Country: USA

Publications

  1. ncbi request reprint Molecular targets of nitric-oxide-donating aspirin in cancer
    K Kashfi
    Department of Physiology and Pharmacology, City University of New York Medical School, NY 10031, USA
    Biochem Soc Trans 33:701-4. 2005
  2. ncbi request reprint NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells
    Adam Spiegel
    Division of Cancer Prevention, SUNY at Stony Brook, Stony Brook, NY 11794 5200, USA
    Biochem Pharmacol 70:993-1000. 2005
  3. ncbi request reprint NO-donating aspirin induces phase II enzymes in vitro and in vivo
    Jianjun Gao
    Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, NY 11794, USA
    Carcinogenesis 27:803-10. 2006
  4. pmc Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets β-catenin
    Niharika Nath
    Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, New York, NY, USA
    Drug Des Devel Ther 7:389-96. 2013
  5. pmc Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition
    Ravinder Kodela
    Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, New York, New York 10031, USA
    J Pharmacol Exp Ther 345:85-94. 2013
  6. pmc Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras
    Khosrow Kashfi
    Department of Physiology and Pharmacology, Sophie Davis School of Biomedical Education, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA
    Biochem Pharmacol 85:689-703. 2013
  7. ncbi request reprint Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention
    Khosrow Kashfi
    Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA
    Biochem Pharmacol 70:969-86. 2005
  8. ncbi request reprint The mechanism of action of nitric oxide-donating aspirin
    Khosrow Kashfi
    Department of Physiology and Pharmacology, City University of New York Medical School, New York, NY 10031, USA
    Biochem Biophys Res Commun 358:1096-101. 2007
  9. doi request reprint NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation
    Mitali Chattopadhyay
    Department of Physiology and Pharmacology, City University of New York Medical School, NY 10031, USA
    Cancer Lett 298:204-11. 2010
  10. ncbi request reprint NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression
    Niharika Nath
    Department of Physiology and Pharmacology, City University of New York Medical School, New York, NY 10031, USA
    Biochem Biophys Res Commun 326:93-9. 2005

Collaborators

Detail Information

Publications27

  1. ncbi request reprint Molecular targets of nitric-oxide-donating aspirin in cancer
    K Kashfi
    Department of Physiology and Pharmacology, City University of New York Medical School, NY 10031, USA
    Biochem Soc Trans 33:701-4. 2005
    ..p.m. in the diet)-treated animals (P<0.001). There was no statistically significant effect by traditional ASA at equimolar doses. Our data indicate that NO-ASA is a highly promising agent for the prevention and/or treatment of cancer...
  2. ncbi request reprint NO-donating aspirin inhibits both the expression and catalytic activity of inducible nitric oxide synthase in HT-29 human colon cancer cells
    Adam Spiegel
    Division of Cancer Prevention, SUNY at Stony Brook, Stony Brook, NY 11794 5200, USA
    Biochem Pharmacol 70:993-1000. 2005
    ..These findings indicate that NO-ASA profoundly inhibits both the expression and enzymatic activity of NOS2 and suggest that these effects may represent an important mechanism for the colon cancer chemopreventive effect of NO-ASA...
  3. ncbi request reprint NO-donating aspirin induces phase II enzymes in vitro and in vivo
    Jianjun Gao
    Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, NY 11794, USA
    Carcinogenesis 27:803-10. 2006
    ..Thus NO-ASA induces phase II enzymes, at least in part, through the action of NO that it releases and by modulating the Keap1-Nrf2 pathway; this effect may be part of its mechanism of action against colon and other cancers...
  4. pmc Flurbiprofen benzyl nitrate (NBS-242) inhibits the growth of A-431 human epidermoid carcinoma cells and targets β-catenin
    Niharika Nath
    Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, New York, NY, USA
    Drug Des Devel Ther 7:389-96. 2013
    ..Previously we showed that an aromatic spacer enhanced the potency of a particular NO-NSAID compared to an aliphatic spacer...
  5. pmc Positional isomers of aspirin are equally potent in inhibiting colon cancer cell growth: differences in mode of cyclooxygenase inhibition
    Ravinder Kodela
    Department of Physiology, Pharmacology, and Neuroscience, Sophie Davis School of Biomedical Education, City University of New York Medical School, New York, New York 10031, USA
    J Pharmacol Exp Ther 345:85-94. 2013
    ..The mechanism of gastric ulcer formation exerted by aspirin and its two isomers warrants a more detailed and thorough investigation...
  6. pmc Biology and therapeutic potential of hydrogen sulfide and hydrogen sulfide-releasing chimeras
    Khosrow Kashfi
    Department of Physiology and Pharmacology, Sophie Davis School of Biomedical Education, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA
    Biochem Pharmacol 85:689-703. 2013
    ..The newly reported NOSH-aspirin that releases both NO and H2S has also been discussed...
  7. ncbi request reprint Non-COX-2 targets and cancer: expanding the molecular target repertoire of chemoprevention
    Khosrow Kashfi
    Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, USA
    Biochem Pharmacol 70:969-86. 2005
    ....
  8. ncbi request reprint The mechanism of action of nitric oxide-donating aspirin
    Khosrow Kashfi
    Department of Physiology and Pharmacology, City University of New York Medical School, New York, NY 10031, USA
    Biochem Biophys Res Commun 358:1096-101. 2007
    ..We propose a mechanism of action of NO-ASA involving formation of quinone methide from its para and ortho isomers and of a carbocation from the meta, with the NO-releasing group functioning as a leaving group...
  9. doi request reprint NO-releasing NSAIDs suppress NF-κB signaling in vitro and in vivo through S-nitrosylation
    Mitali Chattopadhyay
    Department of Physiology and Pharmacology, City University of New York Medical School, NY 10031, USA
    Cancer Lett 298:204-11. 2010
    ..These data provide a mechanistic role for NO and a rational for the chemopreventive effects of NO-NSAIDs...
  10. ncbi request reprint NO-donating aspirin inhibits the growth of leukemic Jurkat cells and modulates beta-catenin expression
    Niharika Nath
    Department of Physiology and Pharmacology, City University of New York Medical School, New York, NY 10031, USA
    Biochem Biophys Res Commun 326:93-9. 2005
    ..A denitrated analog of p-NO-ASA did not degrade beta-catenin indicating the importance of the NO-donating moiety. Our findings suggest that NO-ASA merits further study as an agent against leukemia...
  11. ncbi request reprint Nitric oxide-donating nonsteroidal anti-inflammatory drugs inhibit the growth of various cultured human cancer cells: evidence of a tissue type-independent effect
    Khosrow Kashfi
    American Health Foundation, Valhalla, New York, USA
    J Pharmacol Exp Ther 303:1273-82. 2002
    ..These results raise the possibility that NO-NSAIDs possess chemopreventive and/or chemotherapeutic activity against a wide variety of human cancers...
  12. ncbi request reprint Is COX-2 a 'collateral' target in cancer prevention?
    K Kashfi
    Department of Physiology and Pharmacology, City University of New York Medical School, NY 10031, USA
    Biochem Soc Trans 33:724-7. 2005
    ..The multiple COX-2-independent targets, and the limitations of COX-2 inhibitors, suggest the need to explore targets other than COX-2...
  13. doi request reprint Nitro-aspirin inhibits MCF-7 breast cancer cell growth: effects on COX-2 expression and Wnt/beta-catenin/TCF-4 signaling
    Niharika Nath
    Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
    Biochem Pharmacol 78:1298-304. 2009
    ..p-NO-ASA blocked the cell cycle transition at S to G2/M phase. These studies suggest a targeted chemopreventive/chemotherapeutic potential for NO-ASA against breast cancer...
  14. doi request reprint Anti-inflammatory agents as cancer therapeutics
    Khosrow Kashfi
    Department of Physiology and Pharmacology, Sophie Davis School of Biomedical Education, The City College of the City University of New York, New York 10031, USA
    Adv Pharmacol 57:31-89. 2009
    ..This chapter reviews these classes of compounds, their utility and mechanism(s) of action against the background of mediators that link inflammation and cancer...
  15. pmc Nitric oxide-donating aspirin inhibits beta-catenin/T cell factor (TCF) signaling in SW480 colon cancer cells by disrupting the nuclear beta-catenin-TCF association
    Niharika Nath
    Department of Physiology and Pharmacology, City University of New York Medical School, New York, NY 10031
    Proc Natl Acad Sci U S A 100:12584-9. 2003
    ..This effect, occurring at NO-ASA concentrations far below those required to inhibit cell growth, may be a critical early event in the chemopreventive activity of NO-ASA against colon cancer...
  16. pmc Comparison between 3-Nitrooxyphenyl acetylsalicylate (NO-ASA) and O2-(acetylsalicyloxymethyl)-1-(pyrrolidin-1-yl)diazen-1-ium-1,2-diolate (NONO-ASA) as safe anti-inflammatory, analgesic, antipyretic, antioxidant prodrugs
    Mitali Chattopadhyay
    Department of Physiology and Pharmacology, City University of New York Medical School, 138th St and Convent Ave, New York, NY 10031, USA
    J Pharmacol Exp Ther 335:443-50. 2010
    ..These results underscore the use of N-diazeniumdiolate moieties in drug design...
  17. doi request reprint Modulation of stress genes expression profile by nitric oxide-releasing aspirin in Jurkat T leukemia cells
    Niharika Nath
    Department of Life Sciences, New York Institute of Technology, New York, NY 10023, USA
    Biochem Pharmacol 79:1759-71. 2010
    ..The altered gene expression patterns by NO-ASA in Jurkat T cells suggest mechanisms for carcinogen metabolism, anti-proliferative activity and possible chemoprotective activity in T-ALL...
  18. doi request reprint JS-K, a nitric oxide-releasing prodrug, modulates ß-catenin/TCF signaling in leukemic Jurkat cells: evidence of an S-nitrosylated mechanism
    Niharika Nath
    Department of Physiology and Pharmacology, City University of New York Medical School, 138th Street and Convent Avenue, New York, NY 10031, United States
    Biochem Pharmacol 80:1641-9. 2010
    ..The NO scavenger PTIO abrogated the JS-K mediated degradation of β-catenin demonstrating the need for NO...
  19. ncbi request reprint Growth inhibition of human colon cancer cells by nitric oxide (NO)-donating aspirin is associated with cyclooxygenase-2 induction and beta-catenin/T-cell factor signaling, nuclear factor-kappaB, and NO synthase 2 inhibition: implications for chemopreventi
    Jennie L Williams
    American Health Foundation Cancer Center, Institute for Cancer Prevention, 1 Dana Road, Valhalla, NY 10595, USA
    Cancer Res 63:7613-8. 2003
    ..We propose a model incorporating the pleiotropic effects of NO-ASA on cell signaling and postulate that collectively these effects may contribute to its strong chemopreventive effect...
  20. ncbi request reprint NO-donating aspirin inhibits intestinal carcinogenesis in Min (APC(Min/+)) mice
    Jennie L Williams
    American Health Foundation Cancer Center, Institute for Cancer Prevention, Valhalla, NY 06595, USA
    Biochem Biophys Res Commun 313:784-8. 2004
    ..Our findings establish the strong inhibitory effect of NO-ASA in intestinal carcinogenesis in the Min mouse and suggest that this agent merits further evaluation as a chemopreventive agent against colon cancer...
  21. ncbi request reprint Cancer prevention: a new era beyond cyclooxygenase-2
    Basil Rigas
    Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony Brook, NY 11794 8160, USA
    J Pharmacol Exp Ther 314:1-8. 2005
    ..Given the limitations of COX-2-specific inhibitors and the biological evidence mentioned above, we suggest that targets other than COX-2 should be pursued as alternative or complementary approaches to cancer prevention...
  22. ncbi request reprint NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property?
    Raymond K Yeh
    American Health Foundation Cancer Center, Institute for Cancer Prevention, Valhalla, NY 06595, USA
    Biochem Pharmacol 67:2197-205. 2004
    ..Our findings suggest that the enhanced potency imparted on NSAIDs by this structural modification represents a pharmacological property that may be a general one for this class of compounds...
  23. ncbi request reprint Nitric oxide-donating aspirin prevents pancreatic cancer in a hamster tumor model
    Nengtai Ouyang
    Division of Cancer Prevention, State University of New York at Stony Brook, Stony Brook, New York 11794 5200, USA
    Cancer Res 66:4503-11. 2006
    ..NO-ASA merits further evaluation as a chemopreventive agent against pancreatic cancer...
  24. ncbi request reprint Nitric-oxide-donating NSAIDs as agents for cancer prevention
    Basil Rigas
    Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony Brook, NY 11794 8160, USA
    Trends Mol Med 10:324-30. 2004
    ..The apparent safety and superior efficacy of NO-NSAIDs makes them promising chemopreventive agents against cancer...
  25. ncbi request reprint In vitro metabolism of nitric oxide-donating aspirin: the effect of positional isomerism
    Jianjun Gao
    Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony Brook, NY 11794 8160, USA
    J Pharmacol Exp Ther 312:989-97. 2005
    ....
  26. ncbi request reprint Positional isomerism markedly affects the growth inhibition of colon cancer cells by nitric oxide-donating aspirin in vitro and in vivo
    Khosrow Kashfi
    Division of Cancer Prevention, Department of Medicine, SUNY at Stony Brook, Stony Brook, NY 11794 8160, USA
    J Pharmacol Exp Ther 312:978-88. 2005
    ..Thus, positional isomerism is critical for the pharmacological properties of NO-ASA against colon cancer and it should be taken into consideration in rational drug design...
  27. ncbi request reprint Colon cancer prevention with NO-releasing NSAIDs
    Chatargy S Kaza
    American Health Foundation, Valhalla, NY 10595, USA
    Prostaglandins Other Lipid Mediat 67:107-20. 2002
    ..In this review we discuss salient features of their pharmacology, in vitro and animal data pertaining to colon cancer, their mechanisms of action, and assess their potential in the chemoprevention of colon cancer...